^
    3d
    ARST1321: Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (clinicaltrials.gov)
    P2/3, N=140, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    doxorubicin hydrochloride • pazopanib • cyclophosphamide • ifosfamide • daunorubicin
    9d
    NCI-2019-08556: Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • polyinosinic:polycytidylic acid (BO-112)
    9d
    Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (clinicaltrials.gov)
    P3, N=325, Recruiting, Advenchen Laboratories, LLC | Active, not recruiting --> Recruiting | Trial completion date: Jun 2025 --> Dec 2028 | Trial primary completion date: Dec 2024 --> Dec 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Focus V (anlotinib) • dacarbazine • midazolam hydrochloride
    9d
    A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions (clinicaltrials.gov)
    P1, N=18, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open
    |
    TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1)
    |
    gemcitabine • Fyarro (nanoparticle albumin-bound rapamycin)
    12d
    Proteomics and single-cell transcriptomics identify LRP1 as a diagnostic biomarker for atypical fibroxanthoma and pleomorphic dermal sarcoma. (PubMed, bioRxiv)
    When used in conjunction with LTBP2, specificity for AFX/PDS within the differential rises from 73% to 93%. These findings suggest that LRP1, particularly if evaluated in conjunction with existing stains, can improve diagnostic accuracy for AFX and PDS.
    Journal
    |
    MME (Membrane Metalloendopeptidase) • LRP1 (LDL Receptor Related Protein 1)
    15d
    A new paradigm for retroperitoneal leiomyosarcoma: integrating transcriptomic subtyping and surgical risk stratification for AI-guided drug repurposing. (PubMed, Oncol Rev)
    The AI-guided screening of approved and investigational drug libraries to identify compounds predicted to reverse subtype-specific molecular programs; preclinical studies highlight candidates such as pazopanib and histone deacetylase (HDAC) inhibitors is discussed...Integrating surgical management, multi-omics, and computational pharmacology helps bridge the gap from bench to bedside and, ultimately, improve outcomes for patients with RLMS. In contrast to prior work that addresses molecular subtyping or surgical management in isolation, this review presents an integrative framework that links surgical risk stratification with transcriptomic profiling to enable AI-guided drug repurposing and provides a roadmap for personalized RLMS therapy.
    Review • Journal
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    pazopanib
    17d
    Localized Leiomyosarcoma Biomarker Protocol (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2026 --> Jun 2026
    Trial completion date • Trial primary completion date • Circulating tumor DNA
    19d
    Hepatic carcinosarcoma: a rare and aggressive case with unusual molecular signature! (PubMed, Front Oncol)
    Paclitaxel-carboplatin chemotherapy was commenced with dose modifications for hepatotoxicity, complicated by infusion reactions, mild neuropathy, and mucositis. This case underlines the extreme morphological and molecular heterogeneity of hepatic carcinosarcomas, the rapid progression despite surgery, and the limited systemic treatment options available for such rare tumours.
    Journal
    |
    BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • KIAA1549 • ALPP (Alkaline Phosphatase, Placental) • GPC3 (Glypican 3) • TP63 (Tumor protein 63) • MYOD1 (Myogenic Differentiation 1)
    |
    BRAF fusion
    |
    carboplatin • paclitaxel
    22d
    LMS-HOPE: A Trial for Advanced Leiomyosarcoma With Human Organoid-guided Personalized Efficacy (clinicaltrials.gov)
    P=N/A, N=50, Enrolling by invitation, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New trial
    |
    doxorubicin hydrochloride
    26d
    DAPPER: Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, University Health Network, Toronto | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date • IO biomarker • Pan tumor
    |
    HRD (Homologous Recombination Deficiency)
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
    29d
    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma (clinicaltrials.gov)
    P2, N=20, Recruiting, University of Colorado, Denver | Initiation date: Dec 2025 --> Dec 2026
    Trial initiation date
    |
    pegylated liposomal doxorubicin
    1m
    Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working (clinicaltrials.gov)
    P2/3, N=73, Active, not recruiting, National Cancer Institute (NCI) | N=190 --> 73 | Trial completion date: Mar 2030 --> Jan 2027
    Enrollment change • Trial completion date
    |
    Lynparza (olaparib) • temozolomide • pazopanib • Yondelis (trabectedin)